FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling. (Q52205708)

27 April 2018

title

FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling. (English)

1 reference

27 April 2018

0 references

Davit B

1

1 reference

27 April 2018

Reynolds K

2

1 reference

27 April 2018

Yuan R

3

1 reference

27 April 2018

Ajayi F

4

1 reference

27 April 2018

Conner D

5

1 reference

27 April 2018

Fadiran E

6

1 reference

27 April 2018

Gillespie B

7

1 reference

27 April 2018

Sahajwalla C

8

1 reference

27 April 2018

Huang SM

9

1 reference

27 April 2018

Lesko LJ

10

1 reference

27 April 2018

publication date

1 September 1999

1 reference

27 April 2018

The Journal of Clinical Pharmacology

published in

1 reference

27 April 2018

volume

39

1 reference

27 April 2018

page(s)

899-910

1 reference

27 April 2018

issue

9

1 reference

27 April 2018

Assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: study design and data analysis issues

cites work

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008515

Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008515

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008515

Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008515

Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008515

In vitro approaches to predicting drug interactions in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008515

Saquinavir. Clinical pharmacology and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008515

Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008515

HIV-1 protease inhibitors. A review for clinicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008515

Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008515

Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008515

Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008515

Cytochrome P-450 complex formation by dirithromycin and other macrolides in rat and human livers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008515

Clinical pharmacokinetics of alprazolam. Therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008515

Alprazolam is another substrate for human cytochrome P450-3A isoforms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008515

Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008515

A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008515

Topiramate. Clinical profile in epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008515

OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008515

A drug interaction between zafirlukast and theophylline

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008515

Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008515

Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008515

Effects of ketoconazole on digoxin absorption and disposition in rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008515

A fluvoxamine-caffeine interaction study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008515

Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008515

Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008515

Prediction of in vivo drug interaction from in vitro systems exemplified by interaction between verapamil and cimetidine using human liver microsomes and primary hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008515

HIV-1 protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008515

Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008515

Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008515

Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008515

Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008515

Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008515

Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912709922008515

10.1177/00912709922008515

21 January 2018

Identifiers

DOI

1 reference

27 April 2018

PubMed ID

10471980

1 reference

27 April 2018